Incidence and Prevalence of Children's Diffuse Lung Disease in Spain

Torrent‐Vernetta, Alba; Gáboli, Mirella; Castillo‐Corullón, Silvia; Mondéjar-López, Pedro; Santiago, Verónica Sanz; Costa-Colomer, Jordi; Osona, Borja; Torres-Borrego, J.; Serna-Blázquez, Olga de la; Alonso, Sara Bellón; Aguilera, Pilar; Atauri, Álvaro Gimeno Díaz de; Soria, Alfredo Valenzuela; Ayats, Roser; Vicente, Carlos Martín de; González, Valle Velasco; González, José Domingo Moure; Calderín, Elisa María Canino; Pastor-Vivero, María Dolores; Álvarez, M.A.; Rovira‐Amigo, Sandra; Serrano, Ignacio Iglesias; Izquierdo, Ana Díez; Messa, Inés de Mir; Gartner, Sílvia; Navarro, Alexandra; Baz-Redón, Noelia; Carmona, Rosario; Camats-Tarruella, Núria; Fernández‐Cancio, Mónica; Rapp, Christina; Dopazo, Joaquín; Griese, Matthias; Moreno‐Galdó, Antonio

doi:10.1016/j.arbres.2021.06.001

Cited by 26 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T orrent -V ernetta et al [ 72 ] analysed the incidence and prevalence of paediatric interstitial lung disease (chILD) in Spain during 2018–19. They found an average incidence of 8.18 cases/million/year and an average prevalence of 46.39 cases/million, which was higher compared to the UK, Ireland, Germany and Australasia.…”

Section: Group 77: Paediatric Bronchologymentioning

confidence: 99%

ERS International Congress 2021: highlights from the Paediatric Assembly

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Group 77: Paediatric Bronchologymentioning

confidence: 99%

ERS International Congress 2021: highlights from the Paediatric Assembly

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In Germany, an annual incidence rate of 0.13/100 000 children has been calculated,4 whereas a much higher number has been published for Denmark with an incidence rate of 10.76/100 000 5. According to a recent study from Spain, the average incidence amounted to 0.82/100 000 per year; the prevalence was 4.65/100 000 6. Overall, chILD-related mortality is presumed to be around 15%, with deaths within the first 6 months of life being most common 4 7…”

Section: Introductionmentioning

confidence: 99%

Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe

Seidl¹,

Schwerk

Carlens

et al. 2022

Thorax

Self Cite

View full text Add to dashboard Cite

BackgroundNo data on healthcare utilisation and associated costs for the many rare entities of children’s interstitial lung diseases (chILD) exist. This paper portrays healthcare utilisation structures among individuals with chILD, provides a pan-European estimate of a 3-month interval per-capita costs and delineates crucial cost drivers.MethodsBased on longitudinal healthcare resource utilisation pattern of 445 children included in the Kids Lung Register diagnosed with chILD across 10 European countries, we delineated direct medical and non-medical costs of care per 3-month interval. Country-specific utilisation patterns were assessed with a children-tailored modification of the validated FIMA questionnaire and valued by German unit costs. Costs of care and their drivers were subsequently identified via gamma-distributed generalised linear regression models.ResultsDuring the 3 months prior to inclusion into the registry (baseline), the rate of hospital admissions and inpatient days was high. Unadjusted direct medical per capita costs (€19 818) exceeded indirect (€1 907) and direct non-medical costs (€1 125) by far. Country-specific total costs ranged from €8 713 in Italy to €28 788 in Poland. Highest expenses were caused by the disease categories ‘diffuse parenchymal lung disease (DPLD)-diffuse developmental disorders’ (€45 536) and ‘DPLD-unclear in the non-neonate’ (€47 011). During a follow-up time of up to 5 years, direct medical costs dropped, whereas indirect costs and non-medical costs remained stable.ConclusionsThis is the first prospective, longitudinal study analysing healthcare resource utilisation and costs for chILD across different European countries. Our results indicate that chILD is associated with high utilisation of healthcare services, placing a substantial economic burden on health systems.

show abstract

“…The estimated prevalence of chILD varies from 1.3 to 46.5 cases per million children and is lower in children than adults. 1 , 2 , 3 One of the most common entities emerging in infancy is persistent tachypnea of infancy (PTI). 3 , 4 , 5 , 6 Patients with PTI typically present with tachypnea, crackles on auscultation, failure to thrive, and hypoxemia.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 , 3 One of the most common entities emerging in infancy is persistent tachypnea of infancy (PTI). 3 , 4 , 5 , 6 Patients with PTI typically present with tachypnea, crackles on auscultation, failure to thrive, and hypoxemia. 5 , 7 The prognosis is good; however, some patients require oxygen supplementation for several years due to respiratory insufficiency.…”

Section: Introductionmentioning

confidence: 99%

COVID‐19 in patients with persistent tachypnea of infancy

Marczak

Chruściel

Kulus

et al. 2022

Pediatric Pulmonology

View full text Add to dashboard Cite

Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has raised substantial concern for patients with chronic lung diseases. The aim of this study was to evaluate the clinical characteristics and outcomes of coronavirus disease 2019 (COVID‐19) in children with persistent tachypnea of infancy (PTI). Methods Data on the history of COVID‐19, including diagnosis and clinical course of the infection, were collected during the regular follow‐up visits of children previously diagnosed with PTI. The diagnosis of COVID‐19 was based on laboratory criteria recommended by the European Centre for Disease Prevention and Control. Results Between January 1, 2021, and February 28, 2022, 62 patients with PTI (median age 3.7 years; 42 boys, 20 girls) were evaluated. COVID‐19 was diagnosed in 38 patients (61.3%). Sixteen patients (42.1%) were asymptomatic, and 22 (57.9%) were symptomatic. The most common symptoms were rhinorrhea or nasal congestion, cough, and sore throat. Sixteen patients (42.1%) were classified as having a mild course of COVID‐19, three children (7.9%) as moderate, and three children (7.9%) as severe. Follow‐up performed after a median of 6 months (range 3–12 months) revealed that, after COVID‐19, nearly all PTI patients returned to their prior status (32/38, 84.2%); 4 children (10.5%) suffered from exacerbating symptoms of PTI for 1 month. Two children (5.3%) became asymptomatic after COVID‐19. Conclusion The course of SARS‐CoV‐2 infection in children with PTI is usually mild, and the risk of hospitalization is low. The course of PTI did not change after COVID‐19 in most children, and only a few patients experienced an exacerbation.

show abstract

Incidence and Prevalence of Children's Diffuse Lung Disease in Spain

Cited by 26 publications

References 29 publications

ERS International Congress 2021: highlights from the Paediatric Assembly

ERS International Congress 2021: highlights from the Paediatric Assembly

Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe

COVID‐19 in patients with persistent tachypnea of infancy

Contact Info

Product

Resources

About